In the past 18 months, we’ve had now several new approved therapies in diffuse large B-cell lymphoma. Certainly CAR T-cell therapy, and now we have three FDA-approved products. There’s now tafasitamab in combination with lenalidomide, loncastuximab tesirine and along with bendamustine, rituximab and polatuzumab, are all now active combinations in that space. And that session was really going through some of the data and being able to give some of the treatment providers an understanding of potentially how some of those therapies may fit in the treatment landscape and how we may potentially sequence some of those therapies...
In the past 18 months, we’ve had now several new approved therapies in diffuse large B-cell lymphoma. Certainly CAR T-cell therapy, and now we have three FDA-approved products. There’s now tafasitamab in combination with lenalidomide, loncastuximab tesirine and along with bendamustine, rituximab and polatuzumab, are all now active combinations in that space. And that session was really going through some of the data and being able to give some of the treatment providers an understanding of potentially how some of those therapies may fit in the treatment landscape and how we may potentially sequence some of those therapies.